Propel Bio Management, LLC
Q3 2025 13F-HR Holdings
Net value change ($000)
+17,503
(21.2%)
New positions
6
Sold out positions
6
Turnover %
16.8%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q2 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| MIST | 6,774 | 194.9% |
| CLDX | 4,010 | NEW |
| APLT | 3,316 | 94.4% |
| CMPS | 2,922 | NEW |
| NKTR | 2,788 | NEW |
| JSPR | 2,449 | NEW |
| VRDN | 1,942 | NEW |
| DCTH | 1,640 | 53.4% |
| LONA | 618 | NEW |
| TCRX | 491 | 16.2% |
Top Reduces (Value $000, Stocks/ETFs)
| PHAT | -2,343 | -26.5% |
| ACHV | -1,979 | -14.2% |
| PAGP | -1,514 | -6.1% |
| AKRO | -1,346 | -11.0% |
| CAPR | -695 | -100.0% |
| MAAT PHARMA SACA | -452 | -100.0% |
| LONA | -451 | -100.0% |
| Eiger BioPharmaceuticals, Inc. | -423 | -100.0% |
| ABEO | -389 | -7.0% |
| ACHV | -14 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|